BIG MILESTONE - Global guideline recommendations
Introduction
One of the most important characteristics of a pharmacological agent are inclusions into treatment guidelines based on clinical evidence.
Physicians worldwide still receive most of their knowledge updates from reading the relevant literature, be it a new landmark trial, a systematic review about a certain class of drugs or one single agent but it has become increasingly important for them as well if presented and published evidence is strong enough to lead to treatment recommendations.
Stroke guideline recommendations – a consequence of positive and well conducted trials
When the CARS trial was initially published in 2016, showing in a high quality and larger RCT (randomized clinical trial) in stroke that the cerebroprotective agent is indeed very powerful to treat post-stroke motor complications when combined with physiotherapy a new era began for Cerebrolysin®.
In more and more countries a new category of guidelines were developed – neurorehabilitation guidelines which reviewed and – eventually included pharmacological agents.
And whenever such a new guideline in stroke was developed in the last 6-7 years it also included Cerebrolysin® – the author cannot remember any new guideline published within this time frame which omitted this product.
The list of guideline inclusions becomes longer and so increases the acceptance in the global stroke community:
- EAN Guideline
- Austrian Guideline
- Argentinian Guideline
- Belarusian Guideline
- Canadian Guideline
- German Guideline
- Kasach Guideline
- Korean Guideline
- Polish Guideline
- Romanian Guideline
- Russian Guideline
- Uzbek Guideline
Hardly any physician treating stroke will deny that patients significantly benefit from the treatment with Cerebrolysin®, as it would contradict the conviction of so many guideline committees in various regions in the world, the recommendations are the result of very strict search and evaluation methodologies. Please watch also the following video.
TBI-Guidelines
It is an interesting phenomenon that the global burden of traumatic brain injury does not trigger the same interest in the pharmaceutical industry as well as in the medical community to develop new and effective medications, particularly in the field of neurorecovery after brain trauma, which affects over 70 million persons.
But now Cerebrolysin® got also its first TBI guideline inclusion. The Canadian ERABI (Evidence-Based Review of Acquired Brain Injury) guideline included Cerebrolysin® with a 1b recommendation in the domain attention deficits. Get more information here.
While it is still possible that different guideline committees reach different recommendation levels, one aspect is 100% in favor of Cerebrolysin® – it is generally recommended to treat stroke patients with Cerebrolysin® and the treatment should start as early as possible.